Market Forecast News: Biopharmaceutical CDMO to Hit $34.15B by 2030
The report "Biopharmaceutical CDMO Market by Service (Manufacturing, Fill-Finish), Type (Drug Substance, Drug Product), Scale (Clinical), Source (Mammalian), Therapy Area (Oncology), Molecule Type (mAbs, ADC, CGT, Vaccines) - Global Forecast to 2030", is projected to reach USD 34.15 billion by 2030 from USD 22.40 billion in 2025, at a CAGR of 8.8% during the forecast period. The biopharmaceutical contract manufacturing market is experiencing growth, driven by key factors such as industrial collaborations for drug discovery and development, strategic partnerships, and advancements in manufacturing technologies.
Browse 422 market data Tables and 57 Figures spread through 380 Pages and in-depth TOC on "Biopharmaceutical CDMO Market - Global Forecasts to 2030"
View detailed Table of Content here - https://www.marketsandmarkets.com/Market-Reports/biotechnology-ccontract-manufacturing-market-163964739.html
The formulation & fill-finish segment accounted for the second-largest share of the biopharmaceutical contract manufacturing market in 2024.
The global biopharmaceutical contract manufacturing market is divided into four main service categories: manufacturing, formulation & fill-finish, packaging & labeling, and other services. The formulation & fill-finish segment accounts for the second-largest share of the market due to the rising demand for precision in biologics production, which is crucial for the safety, stability, and efficacy of therapeutic products. As the complexity of biologics increases, the demand for specialized services like formulation development, aseptic filling, and packaging is growing. Contract manufacturing organizations (CMOs) are investing in advanced facilities and technologies to meet this demand, while stringent regulatory requirements and the rise of personalized treatments further enhance the need for these services. This segment is expected to continue its growth and play a key role in delivering innovative treatments to patients.
The commercial operations segment is expected to register the highest CAGR during the forecast period.
The commercial operations segment is rapidly growing within the global biopharmaceutical contract manufacturing market, driven by the rising demand for large-scale manufacturing services. The increasing complexity of biologics and advanced therapies necessitates sophisticated facilities and expertise for a smooth transition from clinical trials to commercial production. As approvals for biologics multiply, biopharmaceutical companies turn to CMOs for specialized equipment, state-of-the-art facilities, and trained staff, ensuring compliance with regulatory standards and consistent product quality. Outsourcing allows pharmaceutical firms to concentrate on research, development, and marketing while accessing efficient and flexible manufacturing. Furthermore, advancements in manufacturing technologies and the rise of personalized medicine are fueling this growth, making commercial contract manufacturing essential for the successful global commercialization of complex biopharmaceutical products.
North America accounted for the largest share of the biopharmaceutical contract manufacturing market in 2024.
The biopharmaceutical contract manufacturing market is divided into six regions: North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. North America leads the market due to its strong pharmaceutical and biotech industries. Recent growth is driven by rising demand for biologics, outsourcing trends, and the region's advanced manufacturing capabilities. North America's robust regulatory environment and support for research and development have created an ideal setting for contract manufacturing, making it a preferred choice for global biopharmaceutical firms. The presence of skilled professionals and enhanced infrastructure further solidifies its position as a key hub in the industry.
The key players in the biopharmaceutical contract manufacturing market include Lonza (Switzerland), Thermo Fisher Scientific Inc. (US), WuXi Biologics (China), Catalent, Inc. (US), Samsung Biologics (South Korea), Boehringer Ingelheim International GmbH (Germany), FUJIFILM Holdings Corporation (Japan), AbbVie, Inc. (US), Eurofins Scientific (Luxembourg), GenScript Biotech Corporation (US), AGC Inc. (Japan), Merck KGaA (Germany), JSR Corporation (Japan), IDT Biologika (Germany), Ajinomoto Bio-Pharma (Japan), Agilent Technologies, Inc. (US), and Asahi Kasei Corporation (Japan).
About MarketsandMarkets™
MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report.
MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.
Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.
The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.
Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts.
To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter , LinkedIn and Facebook .
Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Visit Our Website: https://www.marketsandmarkets.com/
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
- What are the Known and Unknown Adjacencies Impacting the Biopharmaceutical Contract Manufacturing Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
